Publication

Article

Cardiology Review® Online

June 2006
Volume23
Issue 6

An elderly man with atrial fibrillation and ischemic stroke risk

A 77-year-old man with atrial fibrillation of more than 10 years duration was admitted to the neurology department with left-sided hemiparesis and aphasia.

A 77-year-old man with atrial fibrillation of more than 10 years duration was admitted to the neurology department with left-sided hemiparesis and aphasia. Mag­netic resonance imaging showed an infarction in the capillary bed of the right middle cerebral artery. Transeso­phageal echocardiogram (TEE) showed a thrombus formation inside the left atrial appendage (LAA). The patient also had hypertension, peripheral artery disease, and coronary artery disease. He had undergone coronary artery bypass graft surgery 13 years earlier and percutaneous transluminal coronary angioplasty 2 years earlier.

At the time of admission, the patient was taking 100 mg of aspirin daily as a blood-thinning measure. Warfarin sodium (Coumadin) therapy had been terminated 4 years earlier because of severe gastrointestinal bleeding. The patient was also taking heparin sodium, which led to complete resolution of the thrombus formation inside the LAA cavity. To prevent further possible thrombi and subsequent cardioembolic events, the patient was referred to our facility for transcatheter LAA occlusion.

Angiography and TEE showed a multilobed LAA with an orifice diameter of 23 mm (Figure). A 32-mm percutaneous LAA transcatheter occlusion (PLAATO) device was implanted into the orifice of the LAA. After the expanded device showed a stable position and proximal and distal contrast injections confirmed good sealing quality of the LAA, the occluder was released. The final implant size shown in the angiogram was 28 mm. The time from venous groin access to removal of the transseptal sheath was 65 minutes; fluoroscopy time was 22 minutes. The patient was discharged from the hospital the next day. He received the designated medications, consisting of aspirin, clopidogrel (Plavix), and prophylaxis treatment for endocarditis. He completed the 1-, 6-, and 12-month follow-up examinations. Since the implantation of the PLAATO system, the patient has been doing well and has not experienced a cardioembolic stroke or a bleeding event.

Related Videos
The APAC Recap: Cardiomyopathy at CAPP Live 2024 with Greg Duck, PA-C | Image Credit: APAC
The APAC Recap: Peripheral Artery Disease at CAPP Live 2024 with Bob Ross, PA-C | Image Credit: APAC
AMG0001 Advances Healing in CLTI with David G. Armstrong, DPM, PhD, and Michael S. Conte, MD | Image Credit: Canva
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
© 2024 MJH Life Sciences

All rights reserved.